96. Crohn disease Clinical trials / Disease details

Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04089514 (ClinicalTrials.gov)	June 30, 2019	12/9/2019	A Real-world Study of Imraldi® Use	Pan-EU Real-World Experience With Imraldi®	Arthritis, Rheumatoid (RA);Axial Spondyloarthritis (axSpA);Arthritis, Psoriatic (PsA);Crohn's Disease (CD);Colitis, Ulcerative (UC)	Drug: Adalimumab	Biogen	NULL	Completed	18 Years	N/A	All	1000		Belgium;Germany;Ireland;Italy;Spain;United Kingdom
2	EUCTR2018-004967-30-GB (EUCTR)	30/04/2019	14/01/2019	Inflammatory Bowel Disease (IBD) Reference product (Humira-adalimumab) and Biosimilar Product (Imraldi-adalimumab) CroSS over Study	IBD Reference and Biosimilar adalimumab CroSS over Study - iBaSS	Crohn’s disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Imraldi Product Name: Imraldi INN or Proposed INN: adalimumab Trade Name: Humira Product Name: Humira INN or Proposed INN: adalimumab	University Hospital Southampton NHS Foundation Trust	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	150	Phase 4	United Kingdom
3	NCT03662919 (ClinicalTrials.gov)	July 2, 2018	6/9/2018	One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study	PERFUSE - One-year Persistence to Treatment of Patients Receiving Flixabi or Imraldi: a French Cohort Study	Arthritis, Rheumatoid;Spondylitis, Ankylosing;Arthritis, Psoriatic;Crohn's Disease;Colitis, Ulcerative	Drug: Infliximab;Drug: Adalimumab	Biogen	NULL	Active, not recruiting	6 Years	N/A	All	2274		France